相关实验视频
Updated: Jun 7, 2025
11:36
Glycan Node Analysis: A Bottom-up Approach to Glycomics
Published on: May 22, 2016
10.3K
作为肝细胞癌的预后生物标志物的甘油药:系统性审查
Nicky Somers1,2, Emma Butaye1,2, Lorenz Grossar1,2
1Department of Gastroenterology and Hepatology, Ghent University Hospital, 9000 Ghent, Belgium.
Oncology letters
|November 12, 2024
概括
N-glycomics,特别是Mac-2结合蛋白糖化异构体 (M2BPGi),可以预测肝细胞癌 (HCC) 的发展和存活在慢性肝病的成年人. 这一系统性审查强调了N-甘氨酸变化作为有价值的预后标志物.
科学领域:
- 生物化学 生物化学
- 在瘤学瘤学.
- 肝病学 肝病学是一种肝病学.
背景情况:
- 肝细胞癌 (HCC) 是一个重大的全球健康挑战,预后不佳.
- 有效的监测和预后评估对于治疗慢性肝病患者的HCC至关重要.
研究的目的:
- 系统地审查N-glycomics在预测患有慢性肝病的成年人中HCC风险方面的有用性.
- 评估N-葡萄糖药在预测HCC患者整体存活率和复发中的作用.
主要方法:
- 对Medline,Embase,Web of Science和Scopus数据库进行了全面的系统审查.
- 包括的研究重点是N-glycomics用于预测HCC发展,生存和复发.
- 数据合成涉及分析队列大小,随访时间和预测性绩效指标.
主要成果:
- 包括30项研究,涉及中位数为144名患者和63.6个月的随访.
- 麦克-2结合蛋白糖解化异构体 (M2BPGi) 是最常被分析的N-糖蛋白.
- M2BPGi显示了0.83的曲线下的中间面积,用于预测HCC发展.
结论:
- N-甘氨酸的变化,特别是M2BPGi水平,在HCC的预后评估中提供了显著的附加值.
- 在监测HCC的发展和预测患者的生存率和复发时,N-glycomics的帮助.
- 这些发现突显了N-糖药作为肝脏疾病管理中的生物标志物的潜力.
更多相关视频
10:59Glycomics-Guided Glycoproteomics Facilitates Comprehensive Profiling of the Glycoproteome in Complex Tumor Microenvironments
Published on: February 7, 2025
929
13:21Chemically-blocked Antibody Microarray for Multiplexed High-throughput Profiling of Specific Protein Glycosylation in Complex Samples
Published on: May 4, 2012
15.7K
相关概念视频
01:25Protein Glycosylation
6.8K
Glycosylation, the most common post-translational modification for proteins, serves diverse functions. Adding sugars to proteins makes the proteins more resistant to proteolytic digestion. Glycosylated proteins can act as markers and receptors to promote cell-cell adhesion. Additionally, they have many essential quality control functions in the cell, such as correct protein folding and facilitating transport of misfolded proteins to the cytosol, which can be degraded.
Glycosylation occurs in...
Glycosylation occurs in...
6.8K
01:15Hypoglycemia and Glucagon
152
Without prolonged fasting, healthy individuals maintain blood glucose levels above 3.5 mM due to a well-adapted neuroendocrine counterregulatory system that effectively prevents acute hypoglycemia, a potentially life-threatening condition. The primary clinical scenarios for hypoglycemia encompass diabetes treatment, inappropriate production of endogenous insulin or insulin-like substances by tumors, and the use of glucose-lowering agents in non-diabetic individuals. Notably, hypoglycemia in the...
152